𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Upregulation of Fas/Fas ligand in inclusion body myositis

✍ Scribed by Ing-Marie Fyhr; Dr Anders Oldfors


Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
497 KB
Volume
43
Category
Article
ISSN
0364-5134

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Expression of Fas and Fas ligand in cuta
✍ Zoi-Toli, Ourania; Meijer, Chris J. L. M.; Oudejans, Joost J.; de Vries, Els; va πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 207 KB πŸ‘ 1 views

Primary cutaneous B-cell lymphomas (CBCLs) represent a rare, but distinct group of B-cell neoplasms with a different clinical behaviour to B-cell lymphomas secondarily involving the skin. Fas-Fas ligand (Fasl) expression was investigated in a group of primary and secondary CBCLs to gain an insight i

Identification of the ligand binding sit
✍ JΓΌrgen Bajorath πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 472 KB πŸ‘ 2 views

Fas (CD95), a member of the tumor necrosis factor receptor superfamily, and its ligand (FasL), a tumor necrosis factor-like protein, are intensely studied because their interaction on the cell surface is critical for the induction of programmed cell death (apoptosis) and the regulation of immune res

Elevation of soluble Fas and soluble Fas
✍ Emmenegger, U.; Zehnder, R.; Frey, U.; Reimers, A.; Spaeth, P.J.; Neftel, K.A. πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 38 KB πŸ‘ 1 views

Derailed T-cell activation can give rise to life-threatening macrophage activation, the final common pathway of the different forms of reactive macrophage activation syndromes (rMAS). Besides inappropriate activation of the immune system, impaired termination of immune responses might be another mec

Prevalence of sporadic inclusion body my
✍ Beverley A. Phillips; Paul J. Zilko; Frank L. Mastaglia πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 114 KB πŸ‘ 2 views

A 10-year retrospective review was conducted to ascertain the prevalence of inclusion body myositis (IBM) in Western Australia. Seventeen patients with sporadic IBM aged 45-90 years were identified and the prevalence of IBM was calculated to be 9.3 Γ— 10 -6 . The prevalence was higher in men (10.9 Γ—